PRVA

As of 2026-09-11, PRVA scores 40out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. PRVA trades at $20.37, 5% above the band ceiling.

PRVA scores 40 out of 100 on QNTM's five-factor model — a low-conviction reading — at 40 the factor profile is among the weaker names in the universe. Its strongest factor is value at 71 (strong), where it screens cheap on the model's valuation inputs, followed by sentiment at 50. The weakest is momentum at 25, where price trend is the soft spot. Among Healthcare stocks it ranks in roughly the top 50% of the Healthcare names the model scores.

On valuation, PRVA is priced near the top of its recent range — the rich end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 44. Same-sector names the model rates nearby include HALO, HNGE, THC.

This is a descriptive factor read on PRVA, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where PRVA sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for PRVA runs $14.34–$19.36. Current price $20.37 sits 5% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.